WP1066 was first introduced in 200720, 21 as a JAK kinase inhibitor in acute myelogenous leukemia and glioma, and now it is used as a STAT3 phosphorylation (Tyr 705 residue) blocker. This evidence concerns the gene STAT3 and central nervous system cancer.